Evidence map›Paper›PMID 42732274›Full record

ArticleCureus2026

Breast Carcinoma En Cuirasse: Proposal of a Novel Diagnostic Criterion.

Lyronne Olivier, Karuna S Gopeesingh

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lyronne OlivierGeneral Surgery/Breast Surgical Oncology, North West Regional Health Authority, Port of Spain, TTO.
Karuna S GopeesinghInterventional Radiology, Image Guided Solutions Limited, Cunupia, TTO.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast carcinoma en cuirasse (CeC) is a rare form of cutaneous metastases, named as such due to the unique "breastplate" appearance. It is described as diffuse cutaneous induration, thickening, fibrosis, and leathery texture, with erythema and/or hyperpigmentation. Limited literature exists on this rare topic, and subsequently, cases can be misdiagnosed and not appropriately or efficiently managed. As such, we propose the preliminary framework for a novel diagnostic criterion. This is a case of a 93-year-old woman presenting with a one-year history of progressive left breast swelling, peau d'orange, acute mastalgia, and chest wall and abdominal "breastplate" appearance on examination. No distinct breast masses were palpable, but examination was limited due to the increased skin thickness and leathery texture. Diagnostic breast and abdominal dermal punch biopsies were done urgently at first consultation. Mammogram, breast ultrasound, and computed tomography (CT) were requested. Histopathology confirmed invasive lobular carcinoma involving the dermis. Immunohistochemistry (IHC) showed positive estrogen receptor (ER) and progesterone receptor (PR). Human epidermal growth factor receptor-2 (HER2) and E-cadherin were negative. Staging CT revealed multiple breast masses, not extending to the skin or chest wall, along with breast and abdominal skin thickening. Since breast mass biopsies were not performed, we cannot ascertain whether the dermal pathological findings were similar to a primary breast mass. However, since dermal histopathology demonstrated a breast primary and there was CT evidence of left breast masses and no evidence for an alternate source of cutaneous metastases, we can say with fair confidence that the histopathology of the breast masses will be similar to that of the dermal punch biopsies. The diagnosis of breast CeC is therefore supported. Breast CeC contraindicates surgical intervention; thus, definitive medical oncological treatment was implemented. Unfortunately, the patient expired before commencing treatment. Breast CeC usually develops after initial therapy, and prognosis is typically poor. Differentiating between stage III inflammatory breast cancer (IBC) and breast CeC is crucial, as the management of the former is with curative intent while the latter is with palliation. We introduce the preliminary framework for a novel diagnostic criterion entitled "OG Triple Assessment of Breast Carcinoma En Cuirasse" to elucidate breast CeC and increase diagnostic efficiency. The criterion details conditions that are all required to be present for the proposed diagnosis: (1) clinical appearance of "breastplate"/"armor," (2) no radiological evidence of the direct extension of primary breast tumor to the skin, and (3) histopathological confirmation of carcinoma within the dermis demonstrating morphological and/or immunohistochemical concordance with breast carcinoma. Breast CeC rarity is evident by its absence in Caribbean-based studies. This being the primary presentation, lobular phenotype, and the only source of metastases made our case even more unique. We aim to introduce breast CeC into Caribbean literature to aid in augmenting pre-existing data. Additionally, establishing future management and diagnostic guidelines, such as the proposed preliminary framework "OG Triple Assessment of Breast Carcinoma En Cuirasse," may aid efficient diagnosis and management and subsequently improve prognosis.

Indexed as

armorbreastbreast cancerbreastplatecarcinoma en cuirassecaribbean healthdiagnostic criterioninflammatory breast cancermetastaticpalliative

Identifiers

PMID42732274
PMCPMC13570578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.